Published in Int J Pharm on November 24, 2007
Novel formulations for antimicrobial peptides. Int J Mol Sci (2014) 0.91
Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains. Braz J Microbiol (2012) 0.85
Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents (2013) 0.82
Antioxidant, Antibacterial, and Cytotoxic Activities of the Ethanolic Origanum vulgare Extract and Its Major Constituents. Oxid Med Cell Longev (2016) 0.79
Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One (2009) 0.79
Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother (2012) 0.78
Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int J Nanomedicine (2013) 0.77
Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother (2013) 0.77
Nanoparticles for Control of Biofilms of Acinetobacter Species. Materials (Basel) (2016) 0.77
Recent Nanotechnology Approaches for Prevention and Treatment of Biofilm-Associated Infections on Medical Devices. Biomed Res Int (2016) 0.75
Enhancement of lung gene delivery after aerosol: a new strategy using non-viral complexes with antibacterial properties. Biosci Rep (2017) 0.75
Pseudomonas aeruginosa-induced lung injury: role of oxidative stress. Microb Pathog (2002) 1.09
Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother (2009) 1.06
Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol (2002) 1.05
Microscopical investigations of nisin-loaded nanoliposomes prepared by Mozafari method and their bacterial targeting. Micron (2007) 0.97
Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2006) 0.97
Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother (2004) 0.94
Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int J Pharm (2008) 0.93
The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv (2004) 0.90
Antimicrobial efficacy of a new antibiotic-loaded poly(hydroxybutyric-co-hydroxyvaleric acid) controlled release system. J Antimicrob Chemother (2004) 0.87
Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells. Can J Physiol Pharmacol (2010) 0.86
Protective Effects of Liposomal N-Acetylcysteine against Paraquat-Induced Cytotoxicity and Gene Expression. J Toxicol (2011) 0.85
Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm (2005) 0.85
Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents (2006) 0.85
Cytotoxicity and gene array analysis of alveolar epithelial A549 cells exposed to paraquat. Chem Biol Interact (2010) 0.85
Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother (2007) 0.84
Liposomes as a carrier for gentamicin delivery: development and evaluation of the physicochemical properties. Int J Pharm (2008) 0.84
Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J Antimicrob Chemother (2010) 0.83
Therapeutic effect of liposomal-N-acetylcysteine against acetaminophen-induced hepatotoxicity. J Drug Target (2013) 0.83
Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int J Pharm (2009) 0.80
Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One (2009) 0.79
Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model. J Antimicrob Chemother (2012) 0.79
Importance of divalent cations in nanolipoplex gene delivery. J Pharm Sci (2007) 0.79
Safety of archaeosome adjuvants evaluated in a mouse model. J Liposome Res (2002) 0.79
Characterization of human septic sera induced gene expression modulation in human myocytes. Int J Clin Exp Med (2009) 0.78
Liposomal antibiotics for the treatment of infectious diseases. Expert Opin Drug Deliv (2013) 0.78
Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother (2012) 0.78
Formulation and evaluation of floating tablet of H2-receptor antagonist. Drug Dev Ind Pharm (2015) 0.78
Hydrogen peroxide stress provokes a metabolic reprogramming in Pseudomonas fluorescens: enhanced production of pyruvate. J Biotechnol (2013) 0.78
Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J Pharm Pharmacol (2011) 0.78
Toxicity of ricin toxin A chain in rats. Drug Chem Toxicol (2012) 0.77
Safety and pharmacokinetic studies of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol or γ-tocopherol in beagle dogs. Toxicol Mech Methods (2013) 0.77
Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin Drug Deliv (2015) 0.77
N-acetylcysteine modulates the cytotoxic effects of Paclitaxel. Chemotherapy (2011) 0.77
Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J Endotoxin Res (2007) 0.77
Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother (2013) 0.77
Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int J Pharm (2008) 0.77
The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles. J Liposome Res (2010) 0.76
Ginseng aqueous extract attenuates the production of virulence factors, stimulates twitching and adhesion, and eradicates biofilms of Pseudomonas aeruginosa. Can J Physiol Pharmacol (2011) 0.76
Mechanism of fibroblast inflammatory responses to Pseudomonas aeruginosa elastase. Microbiology (2014) 0.76
Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa. J Liposome Res (2010) 0.76
Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa. Ther Deliv (2014) 0.75
Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats. Can J Physiol Pharmacol (2013) 0.75
Acute toxicity study of liposomal antioxidant formulations containing N-acetylcysteine, α-tocopherol, and γ-tocopherol in rats. J Liposome Res (2012) 0.75
Treatment of ricin A-chain-induced hepatotoxicity with liposome-encapsulated N-acetylcysteine. J Drug Target (2011) 0.75
Correction: Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med (2016) 0.75
Fumarate metabolism and ATP production in Pseudomonas fluorescens exposed to nitrosative stress. Antonie Van Leeuwenhoek (2014) 0.75
Disposition of 3H-cholesteryl ether labeled liposomes following intravenous administration to mice: comparison with an encapsulated 14C-inulin as aqueous phase marker. Drug Deliv (2003) 0.75